A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials
Background: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and onc...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.01460/full |
| _version_ | 1817976895199772672 |
|---|---|
| author | Qian Wu Qian Wu Yiting Xiong Yiting Xiong Shujuan Zhang Shujuan Zhang Xinling Chen Xinling Chen Fengming Yi Yiping Wei Wenxiong Zhang |
| author_facet | Qian Wu Qian Wu Yiting Xiong Yiting Xiong Shujuan Zhang Shujuan Zhang Xinling Chen Xinling Chen Fengming Yi Yiping Wei Wenxiong Zhang |
| author_sort | Qian Wu |
| collection | DOAJ |
| description | Background: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and once-daily (OD) CCRT, was performed to help clinicians make better decisions.Methods: Relevant randomized controlled trials (RCTs) were collected by searching the PubMed, Ovid MEDLINE, Embase, ScienceDirect, Web of Science, the Cochrane Library, Scopus and Google Scholar databases to assess antitumor effects (overall survival, OS; progression-free survival, PFS; overall response rate, ORR) and toxicity (adverse effects, AEs).Results: We screened 1499 articles and included 5 RCTs including 1421 patients. We found that BID CCRT improved OS (hazard ratio, HR = 0.88, 95% confidence interval, CI 0.78–0.99, p = 0.03), the 1-year OS rate (OSR-1y, risk ratio, RR = 1.07, 95%CI 1.01–1.13, p = 0.03), and OSR-4y (RR = 1.22, 95%CI 1.03–1.43, p = 0.02), with better trends in OSR-2y, OSR-3y, and OSR-5y, compared to OD CCRT. In addition, BID CCRT had a higher complete response (CR, RR = 1.31, 95%CI 1.01–1.70, p = 0.04) than OD CCRT. PFS (HR = 0.92, 95%CI 0.79–1.07, p = 0.29), annual PFS rate, ORR (RR = 0.99, 95%CI 0.93–1.05, p = 0.72), and AEs for all grades (RR = 1.00, 95%CI 0.98–1.01, p = 0.57), and grades 3–5 (RR = 1.02, 95%CI 0.95–1.09, p = 0.60) were similar between the two arms.Conclusions: BID CCRT appears to be better than OD CCRT for limited-stage SCLC, with better antitumor effects (OS, OSR, and CR) and similar AEs. However, the high levels of AEs in both arms should be taken as a sign of caution. More large sample and high-quality RCTs need to be conducted to confirm our conclusions. |
| first_indexed | 2024-04-13T22:08:56Z |
| format | Article |
| id | doaj.art-4f516ad2d6b34b02b6794a7c23a05d18 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T22:08:56Z |
| publishDate | 2020-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4f516ad2d6b34b02b6794a7c23a05d182022-12-22T02:27:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-01-01910.3389/fonc.2019.01460496987A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled TrialsQian Wu0Qian Wu1Yiting Xiong2Yiting Xiong3Shujuan Zhang4Shujuan Zhang5Xinling Chen6Xinling Chen7Fengming Yi8Yiping Wei9Wenxiong Zhang10Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Medical College, Nanchang University, Nanchang, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Medical College, Nanchang University, Nanchang, ChinaJiangxi Medical College, Nanchang University, Nanchang, ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Medical College, Nanchang University, Nanchang, ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaBackground: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and once-daily (OD) CCRT, was performed to help clinicians make better decisions.Methods: Relevant randomized controlled trials (RCTs) were collected by searching the PubMed, Ovid MEDLINE, Embase, ScienceDirect, Web of Science, the Cochrane Library, Scopus and Google Scholar databases to assess antitumor effects (overall survival, OS; progression-free survival, PFS; overall response rate, ORR) and toxicity (adverse effects, AEs).Results: We screened 1499 articles and included 5 RCTs including 1421 patients. We found that BID CCRT improved OS (hazard ratio, HR = 0.88, 95% confidence interval, CI 0.78–0.99, p = 0.03), the 1-year OS rate (OSR-1y, risk ratio, RR = 1.07, 95%CI 1.01–1.13, p = 0.03), and OSR-4y (RR = 1.22, 95%CI 1.03–1.43, p = 0.02), with better trends in OSR-2y, OSR-3y, and OSR-5y, compared to OD CCRT. In addition, BID CCRT had a higher complete response (CR, RR = 1.31, 95%CI 1.01–1.70, p = 0.04) than OD CCRT. PFS (HR = 0.92, 95%CI 0.79–1.07, p = 0.29), annual PFS rate, ORR (RR = 0.99, 95%CI 0.93–1.05, p = 0.72), and AEs for all grades (RR = 1.00, 95%CI 0.98–1.01, p = 0.57), and grades 3–5 (RR = 1.02, 95%CI 0.95–1.09, p = 0.60) were similar between the two arms.Conclusions: BID CCRT appears to be better than OD CCRT for limited-stage SCLC, with better antitumor effects (OS, OSR, and CR) and similar AEs. However, the high levels of AEs in both arms should be taken as a sign of caution. More large sample and high-quality RCTs need to be conducted to confirm our conclusions.https://www.frontiersin.org/article/10.3389/fonc.2019.01460/fulltwice-dailyonce-dailyconcurrent chemoradiotherapylimited-stage small cell lung cancermeta-analysis |
| spellingShingle | Qian Wu Qian Wu Yiting Xiong Yiting Xiong Shujuan Zhang Shujuan Zhang Xinling Chen Xinling Chen Fengming Yi Yiping Wei Wenxiong Zhang A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials Frontiers in Oncology twice-daily once-daily concurrent chemoradiotherapy limited-stage small cell lung cancer meta-analysis |
| title | A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials |
| title_full | A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials |
| title_fullStr | A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials |
| title_full_unstemmed | A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials |
| title_short | A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials |
| title_sort | meta analysis of the efficacy and toxicity of twice daily vs once daily concurrent chemoradiotherapy for limited stage small cell lung cancer based on randomized controlled trials |
| topic | twice-daily once-daily concurrent chemoradiotherapy limited-stage small cell lung cancer meta-analysis |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.01460/full |
| work_keys_str_mv | AT qianwu ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT qianwu ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT yitingxiong ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT yitingxiong ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT shujuanzhang ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT shujuanzhang ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT xinlingchen ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT xinlingchen ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT fengmingyi ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT yipingwei ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT wenxiongzhang ametaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT qianwu metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT qianwu metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT yitingxiong metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT yitingxiong metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT shujuanzhang metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT shujuanzhang metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT xinlingchen metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT xinlingchen metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT fengmingyi metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT yipingwei metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials AT wenxiongzhang metaanalysisoftheefficacyandtoxicityoftwicedailyvsoncedailyconcurrentchemoradiotherapyforlimitedstagesmallcelllungcancerbasedonrandomizedcontrolledtrials |